Development and internal validation of machine learning algorithms for end-stage renal disease risk prediction model of people with type 2 diabetes mellitus and diabetic kidney disease

References

• Reutens AT. Epidemiology of diabetic kidney disease. Med Clin North Am. 2013; 97(1):1–18.
   PubMed Web of Science ®Google Scholar
• Wan EYF, Fong DYT, Fung CSC, et al. Prediction of new onset of end stage renal disease in chinese patients with type 2 diabetes mellitus – a population-based retrospective cohort study. BMC Nephrol. 2017; 18(1): 257.
   PubMed Web of Science ®Google Scholar
• Wysham CH, Gauthier-Loiselle M, Bailey RA, et al. Development of risk models for major adverse chronic renal outcomes among patients with type 2 diabetes mellitus using insurance claims: a retrospective observational study. Curr Med Res Opin. 2020;36(2):219–227.
   PubMed Web of Science ®Google Scholar
• Yang L, Chu TK, Lian J, et al. Individualised risk prediction model for new-onset, progression and regression of chronic kidney disease in a retrospective cohort of patients with type 2 diabetes under primary care in Hong Kong. BMJ Open. 2020;10(7):e035308.
   PubMed Web of Science ®Google Scholar
• Zhang J, Zhang R, Wang Y, et al. The level of serum albumin is associated with renal prognosis in patients with diabetic nephropathy. J Diabetes Res. 2019;2019:1–9.
   Web of Science ®Google Scholar
• Zheng L, Chen X, Luo T, et al. Early-onset type 2 diabetes as a risk factor for end-stage renal disease in patients with diabetic kidney disease. Prev Chronic Dis. 2020;17:E50.
   PubMed Web of Science ®Google Scholar
• Hsing S-C, Lee C-C, Lin C, et al. The severity of diabetic retinopathy is an independent factor for the progression of diabetic nephropathy. J Clin Med. 2020;10(1):3.
   PubMed Web of Science ®Google Scholar
• Radcliffe NJ, Seah J-M, Clarke M, et al. Clinical predictive factors in diabetic kidney disease progression. J Diabetes Investig. 2017;8(1):6–18.
   PubMed Web of Science ®Google Scholar
• Sun L, Shang J, Xiao J, et al. Development and validation of a predictive model for end-stage renal disease risk in patients with diabetic nephropathy confirmed by renal biopsy. PeerJ. 2020;8:e8499.
   PubMed Web of Science ®Google Scholar
• Ravizza S, Huschto T, Adamov A, et al. Predicting the early risk of chronic kidney disease in patients with diabetes using real-world data. Nat Med. 2019;25(1):57–59.
   PubMed Web of Science ®Google Scholar
• Pinsker JE, Shank T, Dassau E, et al. Comment on American Diabetes Association. Approaches to glycemic treatment. Sec. 7. In standards of medical care in diabetes-2015. Diabetes Care. 2015;38(suppl 1):S41–S48.
   Google Scholar
• Tervaert TWC, Mooyaart AL, Amann K, et al. Pathologic classification of diabetic nephropathy. J Am Soc Nephrol. 2010;21(4):556–563.
   PubMed Web of Science ®Google Scholar
• Enders CK. Multiple imputation as a flexible tool for missing data handling in clinical research. Behav Res Ther. 2017;98:4–18.
   PubMed Web of Science ®Google Scholar
• Wang Y, Zhang J, Teng G, et al. Comparison of performance of equations for estimated glomerular filtration rate in Chinese patients with biopsy-proven diabetic nephropathy. Dis Markers. 2019;2019:1–8.
   Web of Science ®Google Scholar
• Palmer BF. Proteinuria as a therapeutic target in patients with chronic kidney disease. Am J Nephrol. 2007;27(3):287–293.
   PubMed Web of Science ®Google Scholar
• Belur Nagaraj S, Pena MJ, Ju W, et al. Machine-learning-based early prediction of end-stage renal disease in patients with diabetic kidney disease using clinical trials data. Diabetes Obes Metab. 2020;22(12):2479–2486.
   PubMed Web of Science ®Google Scholar
• Michelis R, Kristal B, Zeitun T, et al. Albumin oxidation leads to neutrophil activation in vitro and inaccurate measurement of serum albumin in patients with diabetic nephropathy. Free Radic Biol Med. 2013;60:49–55.
   PubMed Web of Science ®Google Scholar
• Michelis R, Kristal B, Snitkovsky T, et al. Oxidative modifications impair albumin quantification. Biochem Biophys Res Commun. 2010;401(1):137–142.
   PubMed Web of Science ®Google Scholar
• Magzal F, Sela S, Szuchman-Sapir A, et al. In-vivo oxidized albumin - a pro-inflammatory agent in hypoalbuminemia. PLoS One. 2017;12(5):e0177799.
   PubMed Web of Science ®Google Scholar
• Leehey DJ, Kramer HJ, Daoud TM, et al. Progression of kidney disease in type 2 diabetes – beyond blood pressure control: an observational study. BMC Nephrol. 2005;6(1):8.
   PubMedGoogle Scholar
• Thomas MC. Anemia in diabetes: marker or mediator of microvascular disease? Nat Clin Pract Nephrol. 2007;3(1):20–30.
   PubMedGoogle Scholar
• Mohanram A, Zhang Z, Shahinfar S, et al. Anemia and end-stage renal disease in patients with type 2 diabetes and nephropathy. Kidney Int. 2004;66(3):1131–1138.
   PubMed Web of Science ®Google Scholar
• Babazono T, Hanai K, Suzuki K, et al. Lower haemoglobin level and subsequent decline in kidney function in type 2 diabetic adults without clinical albuminuria. Diabetologia. 2006;49(6):1387–1393.
   PubMed Web of Science ®Google Scholar
• Eckardt K-U, Bernhardt WW, Weidemann A, et al. Role of hypoxia in the pathogenesis of renal disease. Kidney Int Suppl. 2005;68(99):S46–S51.
   Google Scholar
• Tsai SF, Tarng DC. Anemia in patients of diabetic kidney disease. J Chin Med Assoc. 2019;82(10):752–755.
   PubMed Web of Science ®Google Scholar
• He BB, et al. Relationship between anemia and chronic complications in Chinese patients with type 2 diabetes mellitus. Arch Iran Med. 2015;18(5):277–283.
   PubMed Web of Science ®Google Scholar
• Li Z-C, Cai Y-Z, Tang Z-G, et al. Lipo-prostaglandin E1 improves renal hypoxia evaluated by BOLD-MRI in patients with diabetic kidney disease. Clin Imaging. 2018;50:239–242.
   PubMed Web of Science ®Google Scholar
• Persson P, Palm F. Hypoxia-inducible factor activation in diabetic kidney disease. Curr Opin Nephrol Hypertens. 2017;26(5):345–350.
   PubMed Web of Science ®Google Scholar
• Packer M. Mechanisms leading to differential hypoxia-inducible factor signaling in the diabetic kidney: modulation by SGLT2 inhibitors and hypoxia mimetics. Am J Kidney Dis. 2021;77(2):280–286.
   PubMed Web of Science ®Google Scholar
• Yamanouchi M, Hoshino J, Ubara Y, et al. Value of adding the renal pathological score to the kidney failure risk equation in advanced diabetic nephropathy. PLoS One. 2018;13(1):e0190930.
   PubMed Web of Science ®Google Scholar
• Wang J, Zhao L, Zhang J, et al. Clinicopathologic features and prognosis of type 2 diabetes mellitus and diabetic nephropathy in different age groups: more attention to younger patients. Endocr Pract. 2020;26(1):51–57.
   PubMed Web of Science ®Google Scholar
• Yu SM-W, Bonventre JV. Acute kidney injury and progression of diabetic kidney disease. Adv Chronic Kidney Dis. 2018;25(2):166–180.
   PubMed Web of Science ®Google Scholar